Radionuclide therapy of bone metastases

Breast Care

Volumn 7, Issue 2, 2012, Pages 100-107

  Fischer, Manfred ^a   Kampen, Willm U ^b  

^a Praxis für Radiologie und Nuklearmedizin ^*  (Germany)

^b Nuclear Medicine Spitalerhof   (Germany)

Author keywords

153Sm EDTMP; 223Ra; 89Sr; Bone metastases; Pain palliation; Radionuclides

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; LEXIDRONAM SAMARIUM SM 153; PENTETIC ACID; STRONTIUM 89;

ANALGESIA; BONE MARROW; BONE MATRIX; BONE METASTASIS; BONE PAIN; BONE SCINTISCANNING; BREAST CANCER; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CELL COUNT; CLINICAL TRIAL (TOPIC); EXTERNAL BEAM RADIOTHERAPY; HEMATOPOIETIC TISSUE; HUMAN; LEUKOCYTE COUNT; PAIN; PATIENT MONITORING; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RADIATION DOSE; RADIONUCLIDE THERAPY; REVIEW; THROMBOCYTE COUNT; TREATMENT CONTRAINDICATION; TREATMENT INDICATION;

EID: 84861364077     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000337634     Document Type: Review

References (59)

1. Elgazzar AH, Maxon HR: Radioisotope therapy of cancer related bone pain. In: Limouris GS, Shukla SK (eds): Radionuclides for therapy. Athens, Mediterra Publishers, 1993, pp 111-116.
2. Roodman GD: Mechanisms of bone lesions in multiple myeloma and lymphoma. Cancer 1997; 80:1557-1514.
3. Coleman RE: Skeletal complications of malignancy. Cancer 1997;80:1588-1594.
4. World Health Organisation: Cancer pain relief and palliative care. World Health Organ Tech Rep Ser 1990;804:7-73.
5. Galasko CSB: Mechanisms of lytic and blastic metastatic disease of bone. Clin Orthop 1982; 169:20-27.
6. Kasalický J, Kraská V: The effect of repeated strontium-89 chloride therapy in bone pain palliation in patients with skeletal cancer metastases. Eur J Nucl Med 1998;25:1362-1367.
7. Quattrocchio CC, Piicucchi S, Sammarra M, Santini D, Vincenzi B, Tonini G, Grasso RF, Zobel BB: Bone metastases in breast cancer: higher prevalence of osteoblastic lesions. Radiol Med 2007;112:1049-1059.
8. Tannock I, Gospodarowicz M, Meakin W, Panzarella T, Stewart L, Rider W: Treatment of metastatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 1989;7:590-597.
9. Wagner G: Frequency of pain in patients with cancer. Recent Results Cancer Res 1984;89:64-71.
10. Coleman RE, Smith P, Rubens RD: Clinical course and prognostic factors following bone recurrence from breast cancer. Br J Cancer 1998;77:336-340.
11. Pecher C: Biological investigations with radioactive calcium and strontium: preliminary report on the use of radioactive strontium in the treatment of metastatic bone cancer. Univ Calif Pub Pharmacol 1942;2:117-149.
12. Brucer M: A chronology of nuclear medicine. St. Louis, Heritage Publications, 1990.
13. Brenner W, Kampen WU, Kampen AM, Henze E: Skeletal uptake and soft tissue retention of 186-Re-HEDP and 153-Sm-EDTMP in patients with metastatic bone disease. J Nucl Med 2001; 42:231-236.
14. Blake GM, Zivanovic MA, McEwan AJB, Ackery DM: Sr-89 therapy: strontium kinetics in disseminated carcinoma of the prostate. Eur J Nucl Med 1986;12:447-454.
15. Fettich J, Padhy A, Nair N, et al.: Comparative clinical efficacy and safety of phosphorus-32 and strontium-89 in the palliative treatment of metastatic bone pain: Results of an IAEA coordinated research project. World J Nucl Med 2003;2:226-231.
16. Bouchet LG, Bolch WE, Goddu SM, et al.: Considerations in the selection of radiopharmaceuticals for palliation of bone pain from metastatic osseous lesions. J Nucl Med 2000;41:682-687.
17. Goddu SM, Bbishayee A, Bouchet LG, et al.: Marrow toxicity of 33-P versus 32-P-orthophosphate: implication for therapy of bone pain and bone metastases. J Nucl Med 2000;41:941-951.
18. Hillegonds DJ, Franklin S, Shelton DK, et al.: The management of painful bone metastases with an emphasis on radionuclide therapy. J Natl Med Assoc 2007;99:785-794.
19. Srivastava SC: Treatment of bone and joint pain with electron emitting radiopharmaceuticals. Int J Nucl Med Biol 2004;19:89-97.
20. Srivastava SC, Meinken GE, Li Z, et al.:A novel sythetic method for preparing Sn-117m stannic DTPA for therapeutic use. J Nucl Med 2002;43:372P.
21. Atkins HL, Mausner LF, Srivastava SC, Meinken GE, et al.: Tin-117m(4+)-DTPA for palliation of pain from osseous metstases: a pilot study. J Nucl Med 1995;36:725-729.
22. Larsen RH, Saxtorph H, Skydsgaard M, Borrebaek J, Jonasdottier TJ, et al.: Radiotoxicity of the alpha-emitting bone-seeker 223Ra injected intravenously into mice: histology, clinical chemistry and haematology. In vivo 2006;20:325-332.
23. McEwan AJB: Palliation of bone pain; in Murray IPC, Ell PJ (eds): Nuclear Medicine in Clinical Diagnosis and Treatment. Edinburgh, Churchill Livingston, 1994, pp 877-892.
24. Suomine MI, Rissanen JK, Käkönen R, Mumberg D, Ziegelbauer K, Halleen J, Scholz A: Alpharadin inhibits osteoclast differentiation in vitro and progression of established breast cancer bone metastases in vivo. American Association for Cancer Research Annual Meeting 2011;abstr 2664.
25. Fischer M: Leitlinie für die Radionuklidtherapie bei schmerzhaften Knochenmetastasen. Nuklearmedizin 1999;38:270-272.
26. Lau WF, Hicks R, Binns D: Differential effects of bisphosphonate on Paget?s disease and metastatic prostatic carcinoma bone scan findings. Clin Nucl Med 2001;26:347-348.
27. Maxon HR, Deutsch EA, Thomas SR, Libson K: Re-186 (Sn) HEDP for treatment of multiple metastatic foci in bone: human biodistribution and dosimetric studies. Radiology 1988;166:501-507.
28. Singh A, Holmes RA, Farhangi M, Volkert WA: Human pharmacokinetics of samarium-153 EDTMP in metastatic cancer. J Nucl Med 1989;30: 1814-1818.
29. Lewington V, Parker C, Hindorf C, Flux G, Chittenden S, et al.: Alpharadin, a novel targeted approach for treatment of bone metastases from CRPC-calculated alpha-particle dosimetry compared to a favourable clinical safety profile. American Society of Clinical Oncology Annual Meeting 2010; abstr no 216.
30. Pons F, Herranz R, Garcia A, Vidal-Sicart S, Conill C, Grau JJ, Alcover J, Fuster D, Setoain J: Strontium-89 for palliation of pain from bone metastases in patients with prostate and breast cancer. Eur J Nucl Med 1997;24:1210-1214.
31. McCready VR, O?Sullivan J, Dearnaly D, Cook G: Prediction of response of skeletal metastases from cancer of the prostate to high activity 186-Re HEDP therapy. J Nucl Med 2002;43(suppl): abstr 316.
32. Sciuto R, Tofani A, Festa A, et al.: Short-and long-term effects of 186-Re-1,1-hydroxyethylidene diphosphonate in the treatment of painful bone metastases. J Nucl Med 2000;41:647-654.
33. Zyskowski A, Lamb D, Morum P, et al.: Strontium-89 treatment for prostate cancer bone metastases: does a prostate specific antigen response predict for improved survival? Australian Radiol 2001;45:39-42.
34. Serafini AN: Therapy of metstatic bone pain. J Nucl Med 2001;42:895-906.
35. Fuster D, Herranz R, Vidal-Sicart S, et al.: Usefulness of strontium-89 for bone pain palliation in metastatic breast cancer patients. Nucl Med Commun 2000;21:623-626.
36. Liepe K, Franke W-G, Koch R, et al.: Comparison of rhenium-188, rhenium-186 and strontium in palliation of painful bone metastases. Nuklearmedizin 2000;39:146-151.
37. Krishnamurthy GT, Krishnamurthy S: Invited commentary: Radionuclides for metastatic bone pain palliation: a need for rational re-evaluation in the new millenium. J Nucl Med 2000;41:688-691.
38. Deguchi T, Yang M, Ehara H, et al.: Detection of micrometastatic prostate cancer cells in the bone marrow of patients with prostate cancer. Br J Cancer 1997;75:634-638.
39. Collins C, Eary JF, Donaldson G, et al.: Samarium-153 EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J Nucl Med 1993;34:1839-1844.
40. Resche I, Chatal JF, Pecking, et al.: A dose controlled study of Sm-153 ethylenediaminetetramethylenephosphonate in the treatment of patients with painful bone metastases. Eur J Cancer 1997;33:1583-1591.
41. O?Sullivan JM, McCready VR, Flux G, et al.: High activity rhenium-186 HEDP with autologous blood stem cells rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone. Br J Cancer 2002;86:1715-1720.
42. Palmedo H, Manka-Waluch A, Albers P, et al.: Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: randomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate. J Clin Oncol 2003;21:2869-2875.
43. Biersack HJ, Palmedo H, Andris A, Rogenhofer S, et al.: Palliation and survival after repeated 188Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: a retrospective analysis. J Nucl Med 2011;52:1721-1726.
44. Turner JH, Claringbold PG: A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 thylenediaminetetramethylenephosphonate. Eur J Cancer 1991;27:1084-1086.
45. Sinzinger H, Palumbo B, Özker K: The Vienna protocol and perspectives in radionuclide therapy. Q J Nucl Med Mol Imaging 2011;55:420-430.
46. Bolger JJ, Dearnaley DP, Kirk D, Lewington VJ, et al.: Strontium-89 (Metastron) versus external beam radiotherapy in patients with painful bone metastases secondary to prostate cancer: preliminary report of a multicenter trial. Semin Oncol 1993;20(suppl 2):32-33.
47. Porter AT, McEwan AJB, Powe JE, Reid R, et al.: Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Rad Oncol Biol Phys 1993;25:805-813.
48. Geldof AA, de Rooij L, Versteegh RT, et al.: Combination 186-Re-HEDP and cisplatin supraadditive treatment effects in prostate cancer cells. J Nucl Med 1999;40:667-671.
49. Sciuto R, Festa A, Rea S, et al.: Effects of low-dose cisplatin on 89-Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J Nucl Med 2002;43:79-86.
50. Tu SM, Delpass ES, Jones D, et al.: Strontium-89 combined with doxorubicin in the treatment of patients with androgen independent prostate cancer. Urol Oncol 1997;2:191-197.
51. Tu SM, Millikan RE, Mengistu B, et al.: Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet 2001;357:336-341.
52. Nilsson S, Franzen L, Parker C, et al.: Bone targeted radium-223 in symptomatic, hormone refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 2007;8:587-594.
53. Hiller SM, Kern AM, Maresca KP, Marquis JC, Eckelman WC, Joyal JL, Babich JW: 123I-MIP-1072, a small-molecule inhibitor of prostate-specific membrane antigen is effective at monitoring tumor response to taxane therapy. J Nucl Med 2011;52:1087-1093.
54. Paulus P: Re-186-HEDP in routine use: correlation between dose rate measurements and clinical efficacy. The Update 1995;1:17-20
55. Serafini AN: Samarium Sm-153 lexidronam for the palliation of bone pain associated with metastases. Cancer 2000;88(suppl):2034-2039.
56. Kalesnikov-Gauthier H, Carpenier P, Depreux P, et al.: Evaluation of toxicity and efficacy of 186-Rehydroxyethylidene diphosphonate in patients with painful bone metastases of prostate or breast cancer. J Nucl Med 2000;41:1689-1694.
57. Baziotis N, Yakoumakis E, Zissimopoulos, et al.: Strontium-89 chloride in the treatment of bone metastases from breast cancer. Oncology 1998;55:377-381.
58. Fischer M, Böhme K: Nuklearmedizinische Schmerztherapie bei metastasiertem Prostatakarzinom. Der Nuklearmediziner 1996;5:339-344.
59. Marcus CS, Saeed S, Mlikotic A, Mishkin F, Pham HL, Javellana T, Diestelhorst S, Minami C: Lack of effect of a bisphosphonate (pamidronate disodium) infusion on subsequent skeletal uptake of Sm-153-EDTMP. Clin Nucl Med 2002;27:427-430.